Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Total Non-Current Liabilities (2016 - 2025)

IGC Pharma has reported Total Non-Current Liabilities over the past 15 years, most recently at $137000.0 for Q3 2025.

  • Quarterly Total Non-Current Liabilities fell 27.89% to $137000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $137000.0 through Sep 2025, down 27.89% year-over-year, with the annual reading at $160000.0 for FY2025, 33.61% down from the prior year.
  • Total Non-Current Liabilities was $137000.0 for Q3 2025 at IGC Pharma, down from $140000.0 in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $696000.0 in Q1 2021 and troughed at $137000.0 in Q3 2025.
  • The 5-year median for Total Non-Current Liabilities is $340000.0 (2023), against an average of $353842.1.
  • The largest YoY upside for Total Non-Current Liabilities was 38.92% in 2021 against a maximum downside of 46.73% in 2021.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $534000.0 in 2021, then fell by 25.66% to $397000.0 in 2022, then tumbled by 31.99% to $270000.0 in 2023, then tumbled by 40.0% to $162000.0 in 2024, then decreased by 15.43% to $137000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Total Non-Current Liabilities are $137000.0 (Q3 2025), $140000.0 (Q2 2025), and $160000.0 (Q1 2025).